CY1109010T1 - γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ - Google Patents

γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ

Info

Publication number
CY1109010T1
CY1109010T1 CY20081100726T CY081100726T CY1109010T1 CY 1109010 T1 CY1109010 T1 CY 1109010T1 CY 20081100726 T CY20081100726 T CY 20081100726T CY 081100726 T CY081100726 T CY 081100726T CY 1109010 T1 CY1109010 T1 CY 1109010T1
Authority
CY
Cyprus
Prior art keywords
crystalline form
preparation
pharmaceutical compositions
compositions containing
ivabradine
Prior art date
Application number
CY20081100726T
Other languages
English (en)
Inventor
Stéphane Horvath
Marie-Noelle Auguste
Gérard DAMIEN
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109010(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1109010T1 publication Critical patent/CY1109010T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Abstract

γ-κρυσταλλική μορφή της υδροχλωρικής ιβαβραδίνης του τύπου (I):
CY20081100726T 2005-02-28 2008-07-10 γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ CY1109010T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP06290328A EP1707562B1 (fr) 2005-02-28 2006-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutique qui la contiennent

Publications (1)

Publication Number Publication Date
CY1109010T1 true CY1109010T1 (el) 2014-07-02

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100726T CY1109010T1 (el) 2005-02-28 2008-07-10 γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ

Country Status (42)

Country Link
US (3) US7361650B2 (el)
EP (1) EP1707562B1 (el)
JP (1) JP4628974B2 (el)
KR (1) KR100835447B1 (el)
CN (1) CN100402502C (el)
AP (1) AP1956A (el)
AR (1) AR052926A1 (el)
AT (1) ATE396974T1 (el)
BR (1) BRPI0600796B8 (el)
CA (1) CA2537400C (el)
CO (1) CO5770097A1 (el)
CR (1) CR8249A (el)
CU (1) CU23616B7 (el)
CY (1) CY1109010T1 (el)
DE (1) DE602006001312D1 (el)
DK (1) DK1707562T3 (el)
EA (1) EA008465B1 (el)
ES (1) ES2308689T3 (el)
FR (1) FR2882555B1 (el)
GE (1) GEP20084467B (el)
GT (1) GT200600088A (el)
HK (1) HK1096659A1 (el)
HR (1) HRP20080406T5 (el)
IL (1) IL173959A0 (el)
JO (1) JO2515B1 (el)
MA (1) MA28134A1 (el)
ME (1) ME02747B (el)
MY (1) MY158129A (el)
NO (1) NO338481B1 (el)
NZ (1) NZ545578A (el)
PE (1) PE20061142A1 (el)
PL (1) PL1707562T3 (el)
PT (1) PT1707562E (el)
RS (1) RS50598B (el)
SA (1) SA06270040B1 (el)
SG (1) SG125229A1 (el)
SI (1) SI1707562T1 (el)
TW (1) TWI314143B (el)
UA (1) UA86595C2 (el)
UY (1) UY29406A1 (el)
WO (1) WO2006092492A1 (el)
ZA (1) ZA200601764B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
PT2471780E (pt) 2007-05-30 2015-02-24 Ind Swift Lab Ltd Sais oxalato de ivabradina cristalinos e seus polimorfos
ES2402765T3 (es) 2008-12-22 2013-05-08 Krka, D.D., Novo Mesto Procedimiento de preparación de ivabradina
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2534135A2 (en) 2010-02-12 2012-12-19 KRKA, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP3156399A1 (en) 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
EP2781509B2 (en) * 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ2013767A3 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics Inc LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
ES2308689T3 (es) 2008-12-01
CU20060037A7 (es) 2008-06-30
DE602006001312D1 (de) 2008-07-10
US20080153803A1 (en) 2008-06-26
HRP20080406T3 (en) 2008-09-30
MY158129A (en) 2016-08-30
PE20061142A1 (es) 2006-12-30
AP2006003521A0 (en) 2006-02-28
SG125229A1 (en) 2006-09-29
JP4628974B2 (ja) 2011-02-09
BRPI0600796B8 (pt) 2021-05-25
US20090318417A1 (en) 2009-12-24
JP2006241156A (ja) 2006-09-14
TW200640872A (en) 2006-12-01
UY29406A1 (es) 2006-07-31
PL1707562T3 (pl) 2008-08-29
FR2882555A1 (fr) 2006-09-01
SI1707562T1 (sl) 2008-10-31
HK1096659A1 (en) 2007-06-08
US20060194963A1 (en) 2006-08-31
HRP20080406T5 (en) 2008-11-30
NO338481B1 (no) 2016-08-22
PT1707562E (pt) 2008-07-08
CN1827602A (zh) 2006-09-06
ME02747B (me) 2010-05-07
AU2006200857A1 (en) 2010-01-28
CA2537400C (fr) 2009-12-15
AR052926A1 (es) 2007-04-11
ATE396974T1 (de) 2008-06-15
BRPI0600796B1 (pt) 2019-02-19
DK1707562T3 (da) 2008-10-13
NO20060948L (no) 2006-08-29
SA06270040B1 (ar) 2010-03-23
EA008465B1 (ru) 2007-06-29
AP1956A (en) 2009-02-18
CR8249A (es) 2008-01-21
WO2006092492A1 (fr) 2006-09-08
BRPI0600796A (pt) 2007-08-14
US7361650B2 (en) 2008-04-22
KR20060095499A (ko) 2006-08-31
RS50598B (sr) 2010-05-07
GT200600088A (es) 2006-10-24
KR100835447B1 (ko) 2008-06-09
NZ545578A (en) 2007-02-23
EP1707562B1 (fr) 2008-05-28
US7867996B2 (en) 2011-01-11
GEP20084467B (en) 2008-08-25
EA200600320A1 (ru) 2006-08-25
IL173959A0 (en) 2006-07-05
MA28134A1 (fr) 2006-09-01
FR2882555B1 (fr) 2007-05-04
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
UA86595C2 (ru) 2009-05-12
EP1707562A1 (fr) 2006-10-04
JO2515B1 (en) 2010-03-17
TWI314143B (en) 2009-09-01
CU23616B7 (es) 2011-01-27
ZA200601764B (en) 2007-05-30
CO5770097A1 (es) 2007-06-29

Similar Documents

Publication Publication Date Title
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1120994T1 (el) Καινοτομες συνθεσεις διαλυματος που περιεχουν κυτταρικο παραγοντα και χρηση αυτων για τη θεραπεια τραυματων
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
SE0301700D0 (sv) Novel compounds
CY1108797T1 (el) Α-κρυσταλλικη μορφη του ρανελικου στροντιου, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις που την περιεχουν
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
SE0302811D0 (sv) Novel compounds
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200970156A1 (ru) Пиридизиноновые производные
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
ATE534383T1 (de) Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
NO20092611L (no) Krystallinsk faststoff Rasagilin base
CY1113386T1 (el) Αναστολεις πρωτεασωματος
IL228402A0 (en) Nitro-cyclic compounds, their pharmaceutical preparations and their uses
CY1113267T1 (el) Παραγωγα θειοφαινιου ως αγωνιστες των υποδοσεων s1p1/edg1
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
SE0302139D0 (sv) Novel compounds
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
NO20063293L (no) Farmasoytiske forbindelser